advisory panel on rare disease fall 2015 meeting
play

Advisory Panel on Rare Disease Fall 2015 Meeting Washington, DC - PowerPoint PPT Presentation

Advisory Panel on Rare Disease Fall 2015 Meeting Washington, DC October 30, 2015 Welcome and Plans for the Day Hal Sox, MD Chief Science Officer, PCORI Vincent Del Gaizo Co-Chair, Advisory Panel on Rare Disease, PCORI Housekeeping


  1. QI: shunt infection Patient in Room Figure 2 Sign on OR door restricting traffic Compliance recorded Position head away from the main OR door (overall 74.5%) Ask for antibiotics Clip hair prn Dirt, debris and adhesive material removed Infections: Chloraprep prep applied to surgical field and not washed off Wait 3 minutes • before protocol (n = 896) ___ # scrubbed 8.8% Hand scrub with betadine or chlorhexidine ___ of ___ did handwash correctly Double Glove (non-latex) ___ # who double gloved • on protocol (n = 1571) 5.7% Ioban Antibiotics in ? Incision, No Yes Shunt evaluation, (p = 0.0027) Revision Wait Injection of Vanc/Gent Closure Post op Orders Dressing Include 1 dose of same antibiotic

  2. Surgical technique – ETV/CPC 36 unselected ETV/CPC Better results with more CPC Better results with more experience Implications for learning

  3. Surgical technique – ETV/CPC Retro Prospective obs RCT

  4. VINOH Ventricle Size Involvement in Neuropsychological Outcomes in Pediatric Hydrocephalus Ventricle size vs outcome New hydro Over 5 y old

  5. Challenges Collaboration • pilot data • ability to work together • follow a study protocol • publish together

  6. Maintaining interest Broad participation: a study is being run by a PI from 8 different centers ETV/CPC Mx of IVH Shunt insertion QI to reduce infection Wellons, Vanderbilt Kestle, Utah Whitehead, Kulkarni, Toronto Baylor Biomarkers in PHH Shunt surgery Riva-Cambrin, SLC Limbrick, St Louis Neuropsych Core Data Project Third ventric Riva-Cambrin, Utah Kulkarni, Toronto Implementation Shunt infection Tamber, Pittsburgh Simon, Seattle Transition Cochrane, Vancouver

  7. Academic credit PI

  8. Academic credit PI

  9. Academic credit PI

  10. Collaboration Advantages

  11. Variation Collaboration allows you to 1) identify it 2) manage it – in study plans - in data analysis 3) learn from it

  12. Volume First look Accrual, sample size Power 12000 10000 9647 Procedures 8000 6000 4000 4765 Patients 2000 0

  13. Learning Frequent discussions conf call q 2 weeks Learn from network meeting q 6 months each other study question study design 9 clin epi trained data forms 2 PhD stats data analysis 8 experienced peds neurosurg researchers manuscript prep 10 expert coordinators

  14. Rationale and Methodology of the Entry Site Trial William Whitehead, MD Principal Investigator Texas Children’s Hospital

  15. Shunt Survival Curve in Pediatric Patients Shunt Failure is a major problem for pediatric patients with 40% failure @ 1 year hydrocephalus >50% failure @ 2 years -Drake, Kestle, et.al., Neurosurgery, Vol.43,No.2, August 1998

  16. Hydrocephalus Association Survey Results How important is this research topic to you? Please rank each one using the scale provided. HA Members: Amanda Garzon (Dir Comm and Marketing), Aisha Heath (Dir of Development), Karima Roumila (Dir of Support and Education), Amy Weist (Business Manager), Laurel Fleming, Paul Gross

  17. Entry Site Background Posterior Anterior

  18. Endoscopic Shunt Insertion Trial Away from choroid Not away from choroid

  19. Study Question Using shunt survival as the outcome, what is the best target for CSF shunt ventricular catheters in pediatric patients undergoing first time shunt insertion?

  20. HCRN Study on Ventricular Catheter Location ESIT US Study SDT n=393 n=121 n=344 1999 2010 1995 Study 654 subjects with reviewable scans Population n=858 Follow up Complete follow up= 845 <1 year of follow= 13

  21. Variables • Ventricular Catheter • Other Variables: Location (target) – Age (<1 m; 1-6m; 6- 12m; 1 to 10y; >10y) – Frontal Horn – Surgeon (>10 cases) – Trigone – Etiology of – Body hydrocephalus – Third – Decade of Surgery – Temporal Horn (1990s; 2000s) – Brain – Entry Site (anterior; – Cistern posterior)

  22. Frontal Horn

  23. Trigone

  24. Brain

  25. Anterior v. posterior entry site shunt survival curves 30% failure @ 1 year 36.5% failure @ 2 years Anterior entry Site has better Log rank test, p<0.0001 shunt survival curve

  26. Multivariate Cox Model • Age • Surgeon • Etiology of Hydrocephalus • Decade of Surgery • Entry Site • Ventricular Catheter Location

  27. Results of Cox Proportional Hazard Model Analysis

  28. Background Entry Site Anterior Posterior

  29. Anterior v. posterior entry site survival curves for catheters in frontal horn (n=289) Log rank, p=0.035

  30. Comparison of shunt failure by sub-types A decreased rate of catheter obstruction appears to be The reason for better shunt survival

  31. Entry Site Selection Literature review Medical literature suggests that both entry sites are used commonly.

  32. Entry Site Selection by HCRN Surgeons in the US Study Entry site is usually determined by surgeon preference and not patient factors

  33. Both groups argue that their shunts last longer and are easier to put in.

  34. Is this enough evidence to recommend anterior entry for patients? 30% failure @ 1 year 36.5% failure @ 2 years Log rank test, p<0.0001

  35. Entry Site Posterior Anterior

  36. Study Question • In pediatric hydrocephalus patients who require a VP shunt, does the choice of shunt entry site (anterior or posterior) reduce the rate of shunt failure by 10% or more at 1 year? Hypothesis: Shunt entry site has a significant effect on the subsequent rate of shunt failure.

  37. The Entry Site Trial study protocol

  38. Primary Objective • The primary objective of the Entry Site Trial is to determine in children with hydrocephalus requiring VP shunt, if: – shunt entry site significantly affects the risk of shunt failure at major pediatric centers in North America.

  39. Primary Endpoint The primary endpoint of the study is the occurrence of shunt failure and the time to shunt failure measured from the day of shunt insertion surgery.

  40. Secondary Objective • The secondary objective of the study is to determine if: – Patient quality of life (acutely and chronically) – Total number of shunt revisions – Complication rates (e.g. infections) – Length of surgery and hospital stay – Number of catheter passes to enter ventricle – Location of ventricular catheter Is significantly different between the two treatment groups.

  41. Recruitment • HCRN Centers (9) – Primary Children’s Medical Center, Salt Lake City – Toronto – Birmingham – Houston – Seattle – Pittsburgh – St Louis – Vancouver – Nashville • Informed consent by: – Surgeons at HCRN centers (n=36) – Study coordinators

  42. Inclusion Criteria • <18 years of age at the time of shunt insertion • Clinical evidence of hydrocephalus that requires a simple VP shunt as determined by a pediatric neurosurgeon • No prior history of shunt insertion, but a history of the following are permissible: – external ventricular drain (EVD) – ventricular reservoir – subgaleal shunt – ETV with or without CPC • Ventriculomegaly on imaging

  43. Exclusion Criteria • Active CSF or abdominal infection • CSF leak without hydrocephalus • Pseudotumor cerebri • Hydranencephaly • Loculations within the ventricular system • Other difficulties that would preclude follow-up for 18 months • Bilateral scalp, bone, or ventricular lesion that makes placement of either an anterior or a posterior shunt impracticable • Bilateral slit-like frontal horns or trigones (<3mm) • Require endoscopic procedure prior to shunt placement/ possible shunt placement

Recommend


More recommend